Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CpG oligodeoxynucleotides in asthma.

I Hussain1, J N Kline

  • 1Department of Medicine, University of Iowa, Iowa City 52242. USA. lftikhar-hussain@uiowa.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Development and evaluation of a lateral flow-based portable optical system for determination of the pregnancy status of dairy cows.

Journal of dairy science·2024
Same author

Estimation of genetic components, heterosis and combining ability of elite Pakistani wheat varieties for yield attributing traits and stripe rust response.

Vavilovskii zhurnal genetiki i selektsii·2023
Same author

Evidence of novel Treponema phylotypes implicated in contagious ovine digital dermatitis and association of treponemes with major lameness causing foot pathogens.

Microbial pathogenesis·2023
Same author

Can honey improve the quality of cryopreserved cross bred ram semen added to tris egg yolk extender?

Cryo letters·2023
Same author

Extra-modification of zirconium dioxide for potential photocatalytic applications towards environmental remediation: A critical review.

Journal of environmental management·2022
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

CpG oligodeoxynucleotides (ODNs) show promise for treating asthma by rebalancing immune responses. These novel agents induce beneficial Th1 inflammation while suppressing allergy-promoting Th2 inflammation, potentially reversing asthma

Area of Science:

  • Immunology
  • Allergy and Asthma Research

Background:

  • Asthma prevalence and severity are increasing globally, particularly in industrialized nations.
  • Reduced childhood infection exposure may decrease Th1-type inflammation, leading to increased Th2-type inflammation implicated in asthma and allergic diseases.
  • Current asthma treatments like corticosteroids are ineffective at altering the initial Th2 response to allergens.

Purpose of the Study:

  • To explore the therapeutic potential of CpG oligodeoxynucleotides (ODNs) for asthma.
  • To investigate the ability of CpG ODNs to modulate Th1 and Th2 immune responses.
  • To evaluate the efficacy of CpG ODNs in preventing asthma manifestations in preclinical models.

Main Methods:

  • Administration of CpG ODNs, which contain unmethylated CG dinucleotide motifs.

Related Experiment Videos

  • Induction of Th1 cytokines and suppression of Th2 cytokines.
  • Assessment of asthma manifestations in animal models.

    • Main Results:

    • CpG ODNs potently induce Th1 cytokines and suppress Th2 cytokines.
    • CpG ODNs demonstrated efficacy in preventing asthma manifestations in preclinical studies.
    • These agents have the potential to reverse Th2-type responses to allergens.

    Conclusions:

    • CpG ODNs represent a novel therapeutic approach for asthma.
    • CpG ODNs may restore immune balance by modulating Th1/Th2 responses.
    • Clinical trials are currently underway to further evaluate this promising treatment.